Enhanced detection of genetic mutation to optimize leukemia treatment: Rong He, M.D.
Rong He, M.D., explains how Mayo Clinic Laboratories’ NPM1Q assay can enhance the treatment of acute myeloid leukemia, or AML. The assay can detect all known forms of a genetic mutation that impacts clinical decision-making.
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
(00:32)
Could you please provide a bit about yourself and your background?
(01:39)
Could you please give a basic overview of the NPM1Q test and why we are so pleased to offer it?
(06:56)
Which patients should have this test and when should it be performed? Is it when they are initially diagnosed?
(09:44)
How would translocation 8;21 and inversion 16 tests be incorporated into testing for patients?
(10:41)
How are the results used in patient care?
(13:41)
What alternative tests options are available, and how do they compare with the NPM1Q test?
(16:22)
What considerations would you suggest clinicians keep in mind for patient care?